Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
335
Recruiting, any sponsor type, condition "glioma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting335
- Completed1,177
335 trials
Showing 1 to 25, recently updated first.
National Cancer Institute (NCI)NIH
NCT05432804 · 97 participants (planned) · Start Mar 20, 2023 · Primary completion Jun 30, 2027
Drug: Placebo Administration; Selinexor and 1 more · For: Recurrent Glioblastoma, IDH-Wildtype; Recurrent MGMT-Methylated Glioblastoma
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 41 sites in all
National Cancer Institute (NCI)NIH
NCT05588141 · 96 participants (planned) · Start May 16, 2023 · Primary completion Aug 1, 2028
Drug: Zotiraciclib · For: Brain Tumor; Cancer
Sites: Jacksonville, Florida; Bethesda, Maryland
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasPivotal-lookingRecruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT06465199 · 265 participants (planned) · Start May 13, 2026 · Primary completion May 2033
Drug: Eflornithine (DFMO); AMXT 1501 Dicaprate · For: Atypical Teratoid/Rhabdoid Tumor; Embryonal Tumor With Multilayered Rosettes; Ewing Sarcoma and 4 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Hartford, Connecticut · 16 sites in all
RasCal Therapeutics, Inc.Industry
NCT04678648 · 134 participants (planned) · Start Mar 3, 2021 · Primary completion Mar 16, 2027
Drug: RSC-1255 Dose Escalation; RSC-1255 Dose Expansion · For: Advanced Malignant Solid Neoplasm; RAS Mutation; Lung Cancer and 3 more
Sites: Los Angeles, California; Denver, Colorado; Nashville, Tennessee
NYU Langone HealthAcademic, hospital or other
NCT06829173 · 84 participants (planned) · Start Nov 5, 2025 · Primary completion May 2027
Drug: XRD-0394 · For: High-Grade Glioma
Sites: New York, New York
Nationwide Children's HospitalAcademic, hospital or other
NCT05096481 · 120 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 15, 2028
Drug: PEP-CMV; Temozolomide and 1 more · For: High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Miami, Florida · 13 sites in all
University of FloridaAcademic, hospital or other
NCT07949071 · 18 participants (planned) · Start Mar 12, 2025 · Primary completion Oct 2033
Drug: pp65 RNA LP; pp65/tumor mRNA RNA-LPs" · For: Recurrent High-grade Glioma
Sites: Gainesville, Florida
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT04559230 · 32 participants (planned) · Start Jan 6, 2022 · Primary completion Aug 2027
Drug: Sacituzumab Govitecan · For: Recurrent Glioblastoma
Sites: Cleveland, Ohio; Austin, Texas; San Antonio, Texas
Barbara Ann Karmanos Cancer InstituteAcademic, hospital or other
NCT07735819 · 61 participants (planned) · Start Nov 2026 · Primary completion Jun 30, 2031
Drug: Minocycline 200mg/day · For: Low Grade Glioma; Glioblastoma
Sites: Detroit, Michigan
- ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasRecruiting
Nationwide Children's HospitalAcademic, hospital or other
NCT06838676 · 60 participants (planned) · Start Jul 10, 2025 · Primary completion Jul 2028
Drug: ACT001 · For: Diffuse Intrinsic Pontine Gliomas (DIPG); Progressive DIPG; Refractory DIPG and 2 more
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Miami, Florida · 20 sites in all
- Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT07935889 · 292 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2035
Drug: Fluorodopa F 18; Temozolomide · For: Glioblastoma, IDH-Wildtype
Sites: Scottsdale, Arizona; Jacksonville, Florida; Albert Lea, Minnesota · 8 sites in all
University of FloridaAcademic, hospital or other
NCT06254326 · 12 participants (planned) · Start Sep 19, 2024 · Primary completion Dec 2027
Drug: TTRNA-DC vaccines with GM-CSF; Autologous Hematopoietic Stem cells (HSCs) and 2 more · For: Recurrent Oligodendroglioma; Progressive Oligodendroglioma
Sites: Gainesville, Florida
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT05303519 · 365 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 1, 2028
Drug: safusidenib; Placebo · For: Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 75 sites in all
- Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).Pivotal-lookingRecruiting
BrainChild Bio, IncIndustry
NCT07680439 · 75 participants (planned) · Start Sep 4, 2026 · Primary completion Oct 2028
Drug: BCB-276 · For: Diffuse Intrinsic Pontine Glioma; DIPG; Brain Tumor and 9 more
Sites: Los Angeles, California; Atlanta, Georgia; Chicago, Illinois · 6 sites in all
- A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasRecruiting
Case Comprehensive Cancer CenterAcademic, hospital or other
NCT07003542 · 48 participants (planned) · Start Mar 16, 2026 · Primary completion Jun 2027
Drug: Sitagliptin · For: Glioblastoma; Brain Tumor
Sites: Cleveland, Ohio
National Cancer Center, JapanGovernment (non-federal)
NCT06159478 · 32 participants (planned) · Start Jun 30, 2023 · Primary completion Feb 28, 2028
Drug: Binimetinib 15 MG · For: Low-grade Glioma; Pancreatic Cancer
Sites: Kashiwa, Japan; Fukuoka, Japan; Sapporo, Japan · 6 sites in all
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
NCT07263438 · 59 participants (planned) · Start Nov 3, 2025 · Primary completion Mar 30, 2028
Drug: Trimipramine; Cohort 1: Atezolizumab and 3 more · For: Glioblastoma; Recurrence Tumor
Sites: Basel, Switzerland; Aarau, Switzerland; Bern, Switzerland · 7 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03911388 · 24 participants (planned) · Start Sep 12, 2019 · Primary completion Dec 31, 2027
Drug: G207 · For: Neoplasms, Brain; Glioblastoma Multiforme; Glioblastoma of Cerebellum and 30 more
Sites: Birmingham, Alabama; St Louis, Missouri; Houston, Texas
Debiopharm International SAIndustry
NCT05765812 · 116 participants (planned) · Start May 15, 2023 · Primary completion Sep 2028
Drug: Zedoresertib; Temozolomide · For: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; Astrocytoma, Grade III
Sites: Chicago, Illinois; New York, New York; Dallas, Texas · 16 sites in all
Nationwide Children's HospitalAcademic, hospital or other
NCT05278208 · 65 participants (planned) · Start Nov 21, 2022 · Primary completion Nov 2028
Drug: LUTATHERA® (Lutetium Lu 177 dotatate) · For: High Grade Glioma; Meningioma; Embryonal Tumor and 10 more
Sites: Aurora, Colorado; Cincinnati, Ohio; Columbus, Ohio · 4 sites in all
Northwell HealthAcademic, hospital or other
NCT02861898 · 33 participants (planned) · Start Oct 11, 2016 · Primary completion Dec 2028
Drug: Intra-arterial Cetuximab; Intra-arterial Mannitol · For: Glioblastoma; Brain Cancer; Brain Neoplasm and 4 more
Sites: New York, New York
University of FloridaAcademic, hospital or other
NCT07492316 · 24 participants (planned) · Start Apr 24, 2026 · Primary completion Sep 1, 2030
Drug: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) · For: Recurrent Medulloblastoma
Sites: Washington D.C., District of Columbia; Gainesville, Florida
Northwell HealthAcademic, hospital or other
NCT03213002 · 67 participants (planned) · Start Mar 25, 2018 · Primary completion Jun 2028
Drug: Capecitabine; Temozolomide · For: Glioblastoma Multiforme (GBM); Glioblastoma; Glioma of Brain and 6 more
Sites: New York, New York
ECOG-ACRIN Cancer Research GroupResearch network
NCT06319027 · 100 participants (planned) · Start Apr 11, 2024 · Primary completion May 31, 2027
Drug: Gadolinium-Chelate · For: Glioblastoma, IDH-Wildtype
Sites: Birmingham, Alabama; Los Angeles, California; Jacksonville, Florida · 18 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT07539441 · 26 participants (planned) · Start Apr 10, 2026 · Primary completion Oct 10, 2029
Drug: Mirdametinib · For: Central Nervous System Tumors; Glioma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.